<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521738</url>
  </required_header>
  <id_info>
    <org_study_id>TDU15478</org_study_id>
    <secondary_id>U1111-1210-0180</secondary_id>
    <nct_id>NCT04521738</nct_id>
  </id_info>
  <brief_title>First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of SAR441255 in Lean to Overweight Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To assess the safety and tolerability of SAR441255 after ascending single subcutaneous (SC)&#xD;
      doses&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To assess the pharmacokinetic parameters of SAR441255 in plasma after ascending single SC&#xD;
      doses&#xD;
&#xD;
      To assess the pharmacodynamic effects on glycemic parameters (fasting and postprandial&#xD;
      glucose, C-peptide and insulin)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant is approximately 8 weeks including a 21-day screening and&#xD;
      baseline phase, a 4-day treatment phase and a 28-day follow up period after dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2019</start_date>
  <completion_date type="Actual">September 26, 2019</completion_date>
  <primary_completion_date type="Actual">September 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Screening to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic (PK) parameter: Cmax</measure>
    <time_frame>Baseline to 96 hrs</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUC</measure>
    <time_frame>Baseline to 96 hrs</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: tmax</measure>
    <time_frame>Baseline to 96 hrs</time_frame>
    <description>Time to reach Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacodynamics (PD): glucose profile</measure>
    <time_frame>Baseline to 24 hrs</time_frame>
    <description>Change from baseline in glucose profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD: insulin profile</measure>
    <time_frame>Baseline to 24 hrs</time_frame>
    <description>Change from baseline in insulin profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD: C-peptide profile</measure>
    <time_frame>Baseline to 24 hrs</time_frame>
    <description>Change from baseline in C-peptide profile</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Overweight</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>SAR441255</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, subcutaneous, escalating dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, subcutaneous, matched volume</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR441255</intervention_name>
    <description>Pharmaceutical form:solution for injection&#xD;
Route of administration: subcutaneous</description>
    <arm_group_label>SAR441255</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form:solution for injection&#xD;
Route of administration: subcutaneous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Male and female subjects, between 18 and 55 years of age, inclusive&#xD;
&#xD;
          -  Body Mass Index ≥20 and ≤30 kg/m2&#xD;
&#xD;
          -  Body weight between 65 and 90 kg, inclusive&#xD;
&#xD;
          -  No concomitant medication&#xD;
&#xD;
          -  Fasting Plasma Glucose &lt;126 mg/dL&#xD;
&#xD;
          -  Hemoglobin A1c &lt;6.5%&#xD;
&#xD;
          -  Triglycerides &lt;300 mg/dL&#xD;
&#xD;
          -  Low-density lipoprotein (LDL) Cholesterol &lt;200 mg/dL&#xD;
&#xD;
          -  Permanent sterile or postmenopausal, if female&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any history or presence of clinically relevant cardiovascular, pulmonary,&#xD;
             gastrointestinal, hepatic, renal, metabolic, hematological, neurological,&#xD;
             osteomuscular, articular, psychiatric, systemic, gynecologic (if female), ocular, or&#xD;
             infectious disease, or signs of acute illness.&#xD;
&#xD;
          -  Any medication (including over the counter products and any other herbal/alternative&#xD;
             remedies such as St John's Wort) within 14 days before inclusion or within 5 times the&#xD;
             elimination half-life or pharmacodynamic half-life of the medication; any vaccination&#xD;
             within the last 28 days and any biologics (antibody or its derivatives) given within 4&#xD;
             months before inclusion.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational site number 8400001</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

